Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer

Trial Profile

Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Bladder cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms VESTOR
  • Most Recent Events

    • 29 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 03 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 09 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01827943).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top